MK-3120

Unknown / undisclosed

Phase 1/2Mechanism not established
Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (4)
Bladder Cancer
NCT07222488 · Merck Sharp & Dohme LLC
2025-12-09 – 2029-02-28 · Bladder Cancer, Urinary Bladder Neoplasms
What this study did
Other / comorbidity
NCT06818643 · Merck Sharp & Dohme LLC
2025-03-25 – 2031-03-25 · Advanced Solid Tumors, Malignant Neoplasm
What this study did
NCT05562830 · Merck Sharp & Dohme LLC
2022-11-16 – 2029-02-26 · Urothelial Carcinoma
What this study did

Competitive landscape

This drug's own stage for Bladder Cancer: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
MK-3120: this drugPhase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Enfortumab VedotinApprovedAntibody–drug conjugateNectin-4Partial signal
NCT03474107: Overall Survival (OS) (From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)): Enfortumab Vedotin 1.25 mg/kg 12.88 months (95% CI 10.58 to 15.21) | Chemotherapy 8.97 months (95% CI 8.05 to 10.74)
NCT03219333: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) (Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)): Enfortumab Vedotin - Cohort 1 44 Percentage of Participants (95% CI 35.1 to 53.2) | Enfortumab Vedotin - Cohort 2 51.7 Percentage of Participants (95% CI 40.8 to 62.4)
Nogapendekin Alfa Inbakicept (Anktiva)ApprovedProtein / enzyme therapeuticIL-15 superagonistnot yet gradedNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
CetrelimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
TremelimumabPhase 3Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
VisugromabPhase 2Monoclonal antibodyGDF-15Weak signal
NCT06059547: Two primary endpoints, no significance test reported (exploratory). Pathologic complete response: 33.3% nivolumab + visugromab (n=15 evaluable) vs 7.1% nivolumab + placebo (n=14 evaluable). Objective response by RECIST 1.1: 60.0% vs 14.3%. Major pathologic response (secondary): 66.7% vs 21.4%.
SHR-2005Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
TuvutromstatPhase 1Small moleculeMAT2Anot yet gradedNo reviewed efficacy summary in this indication
Avipendekin Pegol
—(overall)
CytokineIL-15 receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow MK-3120 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
July 2027 (1)
Phase 1/2Bladder CancerRecruiting
Est. primary completion 2027-07-30 · NCT07222488 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
Phase 1/2Advanced Solid Tumors, Malignant NeoplasmRecruiting
Est. primary completion 2028-02-08 · NCT06818643 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
Phase 1/2Urothelial CarcinomaActive not recruiting
Est. primary completion 2029-02-26 · NCT05562830 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
Phase 1/2Bladder CancerRecruiting
Est. primary completion 2031-07-08 · NCT07232602 · CT.gov ↗
What to watch

See the full readout calendar ↗